Mechanisms of sunitinib resistance in renal cell carcinoma and associated opportunities for therapeutics

被引：6
|
作者：
Wang, Yunxia [1 ]
Liu, Xiaolin [1 ]
Gong, Luyao [1 ]
Ding, Weihong [2 ]
Hao, Wenjing [1 ]
Peng, Yeheng [1 ]
Zhang, Jun [1 ]
Cai, Weimin [1 ]
Gao, Yuan [1 ]
机构：
[1] Fudan Univ, Sch Pharm, Shanghai, Peoples R China
[2] Fudan Univ, Huashan Hosp, Dept Urol, Shanghai, Peoples R China
来源：
BRITISH JOURNAL OF PHARMACOLOGY | 2023年 / 180卷 / 23期
基金：
中国国家自然科学基金;
关键词：
biomarkers; drug resistance; renal cell carcinoma; sunitinib; treatment strategies; CONCISE GUIDE; MULTIDRUG-RESISTANCE; KINASE INHIBITORS; TUMOR PROGRESSION; EXPRESSION; PROTEIN; CANCER; POLYMORPHISMS; EFFICACY; THERAPY;
D O I：
10.1111/bph.16252
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Sunitinib is the first-line drug for renal cell carcinoma (RCC) treatment. However, patients who received sunitinib treatment will ultimately develop drug resistance after 6-15 months, creating a huge obstacle to the current treatment of renal cell carcinoma. Therefore, it is urgent to clarify the mechanisms of sunitinib resistance and develop new strategies to overcome it. In this review, the mechanisms of sunitinib resistance in renal cell carcinoma have been summarized based on five topics: activation of bypass or alternative pathway, inadequate drug accumulation, tumour microenvironment, metabolic reprogramming and epigenetic regulation. Furthermore, present and potential biomarkers, as well as potential treatment strategies for overcoming sunitinib resistance in renal cell carcinoma, are also covered.
引用
收藏
页码：2937 / 2955
页数：19
相关论文
共 50 条
  • [21] NGAL Can Alternately Mediate Sunitinib Resistance in Renal Cell Carcinoma
    Yu, Dah-Shyong
    Wu, Chia-Lun
    Ping, Szu-Yuan
    Huang, Yi-Ling
    Shen, Kun-Hung
    JOURNAL OF UROLOGY, 2014, 192 (02): : 559 - 566
  • [22] Analysis of extracellular vesicles as mediators of Sunitinib resistance in renal cell carcinoma
    Zaccagnino, A.
    Wallisch, M.
    Haussecker, J.
    Stoeckle, M.
    Junker, K.
    EUROPEAN UROLOGY, 2022, 81 : S1659 - S1659
  • [23] Identification of MicroRNAs Involved in Resistance to Sunitinib in Renal Cell Carcinoma Cells
    Yamaguchi, Noriya
    Osaki, Mitsuhiko
    Onuma, Kunishige
    Yumioka, Tetsuya
    Iwamoto, Hideto
    Sejima, Takehiro
    Kugoh, Hiroyuki
    Takenaka, Atsushi
    Okada, Futoshi
    ANTICANCER RESEARCH, 2017, 37 (06) : 2985 - 2992
  • [24] Nesprin1 Deficiency Is Associated with Poor Prognosis of Renal Cell Carcinoma and Resistance to Sunitinib Treatment
    Fukushima, Takafumi
    Kobatake, Kohei
    Miura, Kento
    Takemoto, Kenshiro
    Yamanaka, Ryoken
    Tasaka, Ryo
    Kohada, Yuki
    Miyamoto, Shunsuke
    Sekino, Yohei
    Kitano, Hiroyuki
    Goto, Keisuke
    Ikeda, Kenichiro
    Goriki, Akihiro
    Hieda, Keisuke
    Kaminuma, Osamu
    Hinata, Nobuyuki
    ONCOLOGY, 2024, 102 (10) : 868 - 879
  • [25] Acquired resistance to sunitinib is not associated with functional revascularization in 786-O renal cell carcinoma xenografts
    Robinson, Simon P.
    CANCER RESEARCH, 2015, 75
  • [26] NMR-based metabolic profiling reveals mechanisms of sunitinib and pazopanib resistance in renal cell carcinoma cells
    Amaro, F.
    Carvalho, M.
    Bastos, M. D. L.
    Guedes de Pinho, P.
    Pinto, J.
    TOXICOLOGY LETTERS, 2023, 384 : S181 - S181
  • [27] Sunitinib for metastatic renal cell carcinoma
    Mukherji, Deborah
    Larkin, James
    Pickering, Lisa
    FUTURE ONCOLOGY, 2010, 6 (09) : 1377 - 1385
  • [28] SUNITINIB-ASSOCIATED HYPOTHYROIDISM IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
    Sim, S.
    Hayward, K.
    Jagdev, S.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2013, 9 : 43 - 43
  • [29] Skin Cancer Associated With the Use of Sorafenib and Sunitinib for Renal Cell Carcinoma
    Breaker, Kathryn
    Naam, Mary
    La Rosa, Francisco G.
    Flaig, Insley P.
    Flaig, Thomas W.
    DERMATOLOGIC SURGERY, 2013, 39 (07) : 981 - 987
  • [30] Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer
    Elgendy, Mohamed
    Pablo Fusco, Juan
    Segura, Victor
    Dolores Lozano, Maria
    Minucci, Saverio
    Ignacio Echeveste, Jose
    Gurpide, Alfonso
    Andueza, Mapi
    Melero, Ignacio
    Sanmamed, Miguel F.
    Rodriguez Ruiz, Maria
    Calvo, Alfonso
    Ignacio Pascual, Juan
    Maria Velis, Jose
    Minana, Bernardino
    Diez Valle, Ricardo
    Pio, Ruben
    Agorreta, Jackeline
    Abengozar, Marta
    Colecchia, Maurizio
    Brich, Silvia
    Lorenzo Renne, Salvatore
    Guruceaga, Elisabet
    Patino-Garcia, Ana
    Luis Perez-Gracia, Jose
    INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (07) : 1991 - 2001
12345